Her main research concerns Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy. Suzette Delaloge has included themes like Randomized controlled trial, Radiation therapy, Gynecology and Metastasis in her Breast cancer study. Her work in Internal medicine covers topics such as Surgery which are related to areas like Clinical trial and Trastuzumab.
Her Oncology study combines topics in areas such as Neoadjuvant therapy, Circulating tumor cell, Docetaxel and Pathology. Her Cancer study integrates concerns from other disciplines, such as Mutation, Germline, Clinical endpoint, Survival analysis and Family history. Her studies examine the connections between Chemotherapy and genetics, as well as such issues in Anthracycline, with regards to Immunology, Immune system, Logistic regression, Nomogram and Stage.
Her primary areas of investigation include Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. Suzette Delaloge studied Breast cancer and Surgery that intersect with Clinical trial. The Oncology study combines topics in areas such as Randomized controlled trial, Neratinib, Capecitabine and Anthracycline.
Her Cancer study which covers Cancer research that intersects with Immune system. Her Chemotherapy study frequently draws connections to other fields, such as Radiation therapy. Her Metastatic breast cancer research incorporates themes from BRCA mutation and Progression-free survival.
Suzette Delaloge mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. Her Oncology research focuses on Docetaxel and how it relates to Epirubicin. Her work carried out in the field of Breast cancer brings together such families of science as Clinical endpoint, Quality of life, Prospective cohort study and Adjuvant therapy.
Intervention is closely connected to Psychological intervention in her research, which is encompassed under the umbrella topic of Cancer. In her research, Lapatinib is intimately related to Capecitabine, which falls under the overarching field of Metastatic breast cancer. Her work deals with themes such as Gene signature, Randomized controlled trial and Early breast cancer, which intersect with Chemotherapy.
Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Cancer are her primary areas of study. Her research integrates issues of Chemotherapy, Adjuvant therapy, Cohort, Adverse effect and Prospective cohort study in her study of Breast cancer. Suzette Delaloge works mostly in the field of Chemotherapy, limiting it down to topics relating to Tamoxifen and, in certain cases, Randomization, Medical prescription and Therapeutic drug monitoring, as a part of the same area of interest.
Her study in Oncology is interdisciplinary in nature, drawing from both Transcriptome, Randomized controlled trial, Gene signature, Hazard ratio and Biomarker. The study incorporates disciplines such as Taxane, Adjuvant and Anthracycline in addition to Randomized controlled trial. Her studies deal with areas such as Genetic counseling, Susceptibility gene and Family history as well as Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid.
Nature Medicine (2007)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu.
The New England Journal of Medicine (2017)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets.
The New England Journal of Medicine (2016)
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba.
Nature Medicine (2014)
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Alfredo Criollo;Alfredo Criollo;Alfredo Criollo.
Immunological Reviews (2007)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy.
Lancet Oncology (2016)
Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period
Fabrice Andre;Khemaies Slimane;Thomas Bachelot;Arianne Dunant.
Journal of Clinical Oncology (2004)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge.
Lancet Oncology (2017)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale.
Annals of Oncology (2014)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M.E. Robson;N. Tung;P. Conte;S.-A. Im.
Annals of Oncology (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: